Connect Biopharma Holdings Ltd

Connect Biopharma Holdings Ltd (CNTB) priced its initial public offering on Mar 19, 2021 at $17.00 per ADS, within its $15.00–$17.00 range, raising $191.2M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $948.9M. Jefferies was lead-left underwriter, joined by Leerink Partners, Piper Sandler and CICC. Latham & Watkins, Maples and Calder and Han Kun advised the company and Davis Polk and Global Law Office advised the underwriters.

Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company developing therapies for T cell-driven inflammatory diseases, using functional T cell assays to find candidates. Its lead candidate, CBP-201, is an antibody targeting interleukin-4 receptor alpha for atopic dermatitis and asthma.

Status

IPO

Ticker

CNTB

Exchange

Nasdaq Global Market

Priced

Mar 19, 2021

IPO price

$17.00 per ADS

Price range

$15.00–$17.00

Raised

$191.2M

Market cap at IPO price

$948.9M

First filed

Feb 26, 2021

Underwriters

Jefferies, Leerink Partners, Piper Sandler and CICC

Company counsel

Latham & Watkins, Maples and Calder and Han Kun

Underwriters' counsel

Davis Polk and Global Law Office

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.